MedAdvisor new deal with EBOS’s Zest

Company News

by Rachael Jones

MedAdvisor (ASX:MDR) Australia’s leading digital medication management company, is pleased to announce it has formalised its agreement with EBOS subsidiary Zest, following EBOS Group’s investment in MedAdvisor back in October last year.

Under the agreement, MedAdvisor will provide a digital communication channel for Zest’s healthcare programs, enabling better connections with manufacturers and the community.

This partnership may extend further as the Company’s hospital market expansion strategy rolls out, through collaboration on tailored and customised hospital discharge programs. outcomes.

Shares in MedAdvisor (ASX: MDR) are trading flat at 4.2c.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.